Cabiralizumab is under clinical development by Bristol-Myers Squibb and currently in Phase I for Glioblastoma Multiforme (GBM). According to GlobalData, Phase I drugs for Glioblastoma Multiforme (GBM) have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Cabiralizumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Cabiralizumab overview

Cabiralizumab (CSF1R antibody) is under development for the treatment of pigmented villonodular synovitis, biliary tract cancer, other inflammatory disorders, relapsed or refractory multiple myeloma, solid tumors including non-small cell lung cancer, melanoma, head and neck squamous cell carcinoma, colorectal cancer, ovarian cancer, glioblastoma multiforme (GBM), peripheral T cell lymphoma (PTCL) and renal cell carcinoma. The drug candidate is administered as an IV infusion. The drug candidate is a humanized monoclonal antibody targeting colony stimulating factor 1 receptor (CSF1R). The drug candidate is based on receptor-ligand matching technology. The drug candidate was also under development for the treatment of rheumatoid arthritis and multiple sclerosis, diffuse type tenosynovial giant cell tumor, metastatic adenocarcinoma of the pancreas, bile duct cancer (cholangiocarcinoma).

Bristol-Myers Squibb overview

Bristol-Myers Squibb (BMS) is a specialty biopharmaceutical company that is engaged in discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on cancer, immunology, cardiovascular, and fibrotic therapeutic projects. The company offers its products across the world to wholesalers, retail pharmacies, medical professionals, hospitals and government entities. BMS provides its products in the US, Europe, and Japan. The company conducts research to focus on the discovery and development of novel medicines that address serious diseases in areas of significant unmet medical need. BMS is headquartered in Princeton, New Jersey, the US.

For a complete picture of Cabiralizumab’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.